Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients

Neuropsychopharmacology

Volumn 34, Issue 10, 2009, Pages 2323-2328

  Martorana, Alessandro ^a,b   Mori, Francesco ^a   Esposito, Zaira ^a   Kusayanagi, Hajime ^a   Monteleone, Fabrizia ^a   Codecà, Claudia ^a   Sancesario, Giuseppe ^a,b   Bernardi, Giorgio ^b   Koch, Giacomo ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Acetylcholine; Alzheimer's disease; L dopa; Short latency afferent inhibition; Transcranial magnetic stimulation

Indexed keywords

ACETYLCHOLINE; DOPAMINE; LEVODOPA;

ABSENCE OF SIDE EFFECTS; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DOPAMINERGIC SYSTEM; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ACETYLCHOLINE; AGED; ALZHEIMER DISEASE; CEREBRAL CORTEX; DOPAMINE; DOPAMINE AGENTS; ELECTRIC STIMULATION; HUMANS; LEVODOPA; NEURAL INHIBITION; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; STATISTICS AS TOPIC; TIME FACTORS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 68949191029     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.60     Document Type: Article

References (44)

1. Allard PO, Rinne J, Marcusson JO (1994). Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res 637: 262-266.
2. Arendt T, Marcova L, Bigl V, Brückner MK (1995). Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. I. Dendritic organisation of the normal human basal forebrain. J Comp Neurol 351: 169-188.
3. Beckstead RM, Domesick VB, Nauta WJ (1979). Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res 175: 191-217.
4. Berlanga ML, Simpson TK, Alcantara AA (2005). Dopamine D5 receptor localization on cholinergic neurons of the rat forebrain and diencephalon: a potential neuroanatomical substrate involved in mediating dopaminergic influences on acetylcholine release. J Comp Neurol 492: 34-49.
5. Blokland A (1995). Acetylcholine: a neurotransmitter for learning and memory? Brain Res Brain Res Rev 21: 285-300.
6. Brooks DJ (2006). Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. Wien Klin Wochenschr 118: 570-572.
7. Brooks JM, Sarter M, Bruno JP (2007). D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex. Neuropharmacology 53: 455-463.
8. Cao YJ, Surowy CS, Puttfarcken PS (2005). Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release. Neuropharmacology 48: 72-79.
9. Carlesimo GA, Caltagirone C, Gainotti G (1996). The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 36: 378-384.
10. Conti F, Barbaresi P, Melone M, Ducati A (1999). Neuronal and glial localization of NR1 and NR2A/B subunits of the NMDA receptor in the human cerebral cortex. Cereb Cortex 9: 110-120.
11. DeLong MR (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13: 281-285.
12. Di Cara B, Panayi F, Gobert A, Dekeyne A, Sicard D, De Groote L et al (2007). Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 10: 383-399.
13. Del Arco A, Mora F, Mohammed AH, Fuxe K (2007). Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens. J Neural Transm 114: 185-193.
14. Di Lazzaro V, Oliviero A, Profice P, Pennisi MA, Di Giovanni S, Zito G et al (2000). Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res 135: 455-461.
15. Di Lazzaro V, Oliviero A, Tonali PA, Marra C, Daniele A, Profice P et al (2002). Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 13: 392-397.
16. Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Marra C et al (2004). Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psych 75: 555-559.
17. Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Marra C et al (2005). Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J Neurol Neurosurg Psych 76: 1064-1069.
18. Gaykema RP, Zaborszky L (1996). Direct catecholaminergic-cholinergic interactions in the basal forebrain. II. Substantia nigra-ventral tegmental area projections to cholinergic neurons. J Comp Neurol 374: 555-577.
19. Hersi AI, Kitaichi K, Srivastava LK, Gaudreau P, Quirion R (2000). Dopamine D-5 receptor modulates hippocampal acetylcholine release. Brain Res Mol Brain Res 76: 336-340.
20. Ingham CA, bolam JP, Smith AD (1998). GABA-immunoreactive boutons in the rat basal forebrain: comparison of neurons that project to the neocortex with pallidosubthalamic neurones. J Comp Neurol 273: 263-282.
21. Kemppainen N, Laine M, Laakso MP, Kaasinen V, Någren K, Vahlberg T et al (2003). Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 18: 149-154.
22. Kumar U, Patel SC (2007). Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res 1131: 187-196.
23. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E (1993). Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 43: 1927-1934.
24. Löffler M, Bubl B, Huethe F, Hubbe U, McIntosh JM, Jackisch R et al (2006). Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release. Brain Res Bull 68: 361-373.
25. Martorana A, Stefani A, Palmieri MG, Esposito Z, Bernardi G, Sancesario G et al (2008). L-: dopa modulates motor cortex excitability in Alzheimer's disease patients. J Neural Transm 115: 1313-1319.
26. McNeill TH, Koek LL, Haycock JW (1984). The nigrostriatal system and aging. Peptides 5(Suppl 1): 263-268.
27. Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D et al (2007). Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 100: 1047-1061.
28. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN (1995). Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 37: 300-312.
29. Nazarali AJ, Reynolds GP (1992). Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol 12: 581-587.
30. Orth M, Amann B, Robertson MM, Rothwell JC (2005). Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain 128: 1292-1300.
31. Pierantozzi M, Panella M, Palmieri MG, Koch G, Giordano A, Marciani MG et al (2004). Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia. Clin Neurophysiol 115: 2410-2418.
32. Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G et al (1996). Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology 47: 1065-1068.
33. Preda S, Govoni S, Lanni C, Racchi M, Mura E, Grilli M et al (2008). Acute-beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 33: 1062-1070.
34. Reinikainen KJ, Paljärvi L, Halonen T, Malminen O, Kosma VM, Laakso M et al (1988). Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 9: 245-252.
35. Rosen J, Zubenko GS (1991). Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 29: 224-232.
36. Rossini PM, Barker AT, Berardelli A, Caramia MD, Caruso G, Cracco RQ et al (1994). Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 91: 79-92.
37. Sailer A, Molnar GF, Paradiso G, Gunraj CA, Lang AE, Chen R (2003). Short and long latency afferent inhibition in Parkinson's disease. Brain 126: 1883-1894.
38. Sailer A, Cunic DI, Paradiso GO, Gunraj CA, Wagle-Shukla A, Moro E et al (2007). Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. Neurology 68: 356-363.
39. Sarter M, Bruno JP, Turchi J (1999). Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann NY Acad Sci 877: 368-382.
40. Smiley JF, Subramanian M, Mesulam MM (1999). Monoaminergic-cholinergic interactions in the primate basal forebrain. Neuroscience 93: 817-829.
41. Tokimura H, Di Lazzaro V, Tokimura Y, Oliviero A, Profice P, Insola A et al (2000). Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol (Lond) 523: 503-513.
42. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D (1999). Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 66: 184-188.
43. Wu J, Khan GM, Nichols RA (2007). Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 nicotinic receptors. Brain Res 1182-1189.
44. Zaborszky L, Cullinan WE (1996). Direct catecholaminergic-cholinergic interactions in the basal forebrain. I. Dopamine-beta-hydroxylase- and tyrosine hydroxylase input to cholinergic neurons. J Comp Neurol 374: 535-554.